Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 6.71
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also...
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers.
Data is available to registered users only
Buy
Sell